Trending:
Comment
-
21 June 2018
Regenerative therapy for peripheral artery disease moves forward
Encouraging Phase II results were released last week for Pluristem’s PLX-PAD, a placenta-based allogeneic stem cell therapy given intramuscularly, targeting peripheral artery disease (PAD). The positive results are great news...
-
20 June 2018
ViiV ups the ante with positive topline data for its second two-drug HIV combo
On June 14, ViiV Healthcare announced positive topline results from its Phase III GEMINI 1 and GEMINI 2 studies.
-
20 June 2018
Thailand: from medical tourism to contract manufacturing
Thailand hopes to use its strength in medical tourism to grow its pharmaceutical sector, claimed industry experts at the Thailand Board of Investment & TCELS Presents: Life Innovation - Business...
-
20 June 2018
Pharma underutilises avenues to attract and retain trial patients
Pharma companies can better attract patients to clinical trials through working with patient advocacy groups to generate feasible trial designs and offering to offset trial costs, said delegates at Arena...
-
20 June 2018
EMA approval for Trazimera: another win for trastuzumab biosimilars
On May 31, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) positively recommended a marketing authorization to be granted for Pfizer’s Trazimera (trastuzumab), a biosimilar...
-
20 June 2018
EHA 2018: competition is heating up in DLBCL for anti-CD19 CAR-T cell therapies
Numerous highly attended clinical data and educational sessions were hosted about CAR-T cell therapy at this year’s European Hematology Association (EHA) annual meeting.
-
20 June 2018
EAN Congress 2018: refractory migraine and the problem with prevention
Migraine is the most prevalent brain disorder in the world, and yet, until earlier this year, the options for preventative treatment only included a variety of off-label drugs or drugs...
-
20 June 2018
EAN Congress 2018: brain disorders – where is the value?
Brain disorders (mental and neurological disorders) represent 35% of Europe’s total disease burden, and a 2010 study showed that the total cost of this burden amounts to €800bn.
-
19 June 2018
EAN Congress 2018: adaptation key to managing non-routine Parkinson’s
Parkinson’s disease is a chronic and progressive disease which is the second most common movement disorder in elderly patients, after Alzheimer’s disease, affecting up to 2% of patients above 65...
-
19 June 2018
EHA 2018: pivotal Phase III data for Daiichi Sankyo’s quizartinib
Daiichi Sankyo’s pivotal data presentation at this year’s European Hematology Association (EHA) annual meeting showed that its FLT3 inhibitor quizartinib significantly improved patient outcomes in relapsed/refractory (R/R) FLT3-ITD-mutated acute myeloid...
